Needham & Company LLC Reaffirms “Buy” Rating for AtriCure (NASDAQ:ATRC)
Needham & Company LLC reaffirmed their buy rating on shares of AtriCure (NASDAQ:ATRC – Free Report) in a research report sent to investors on Friday,Benzinga reports. They currently have a $51.00 price target on the medical device company’s stock. Several other analysts also recently commented on ATRC. JMP Securities reaffirmed a “market outperform” rating and […]
Needham & Company LLC reaffirmed their buy rating on shares of AtriCure (NASDAQ:ATRC – Free Report) in a research report sent to investors on Friday,Benzinga reports. They currently have a $51.00 price target on the medical device company’s stock. Several other analysts also recently commented on ATRC. JMP Securities reaffirmed a “market outperform” rating and […]
